Which one of the following drugs inhibits neutrophil recruitment?

Explanation

## Correct Answer: B. Febuxostat Febuxostat is a selective xanthine oxidase (XO) inhibitor that reduces uric acid production and has a unique anti-inflammatory mechanism beyond simple urate lowering. The key discriminator is that febuxostat **inhibits neutrophil recruitment** by suppressing the expression of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells and reducing the production of pro-inflammatory cytokines like IL-6 and TNF-α. This occurs through inhibition of NF-κB signaling pathways. In acute gout attacks, neutrophils are the primary inflammatory cells recruited to joints; febuxostat's ability to reduce neutrophil infiltration makes it unique among urate-lowering agents. Unlike allopurinol (another XO inhibitor), febuxostat has superior anti-inflammatory properties that extend beyond uric acid reduction. In Indian clinical practice, febuxostat is increasingly preferred in acute gout management because it reduces both the frequency and severity of flares by dampening the neutrophil-mediated inflammatory cascade. This mechanism is particularly relevant in Indian populations with high prevalence of gout due to dietary purine intake and metabolic syndrome. ## Why the other options are wrong **A. Montelukast** — Montelukast is a cysteinyl leukotriene receptor antagonist used in asthma and allergic rhinitis. While it blocks leukotriene-mediated inflammation, it does NOT directly inhibit neutrophil recruitment. Leukotrienes promote eosinophil recruitment more prominently than neutrophil recruitment. This is an NBE trap pairing anti-inflammatory drugs with neutrophil inhibition without specificity. **C. Colchicine** — Colchicine inhibits microtubule polymerization and reduces neutrophil migration by impairing cytoskeletal dynamics. However, it does NOT specifically inhibit neutrophil recruitment at the adhesion molecule or chemokine receptor level—it acts downstream on cell motility. Febuxostat's upstream inhibition of adhesion molecule expression is more direct and specific for recruitment blockade. **D. Sodium cromolyn** — Sodium cromolyn (cromoglycate) stabilizes mast cells and prevents degranulation, reducing histamine and mediator release in allergic conditions. It does NOT inhibit neutrophil recruitment directly. It is primarily used in asthma and allergic rhinitis, not in conditions driven by neutrophil infiltration. This option conflates mast cell stabilization with neutrophil inhibition. ## High-Yield Facts - **Febuxostat** inhibits neutrophil recruitment by suppressing adhesion molecule expression (ICAM-1, VCAM-1) and NF-κB signaling. - **Xanthine oxidase inhibitors** (febuxostat, allopurinol) lower uric acid, but only febuxostat has potent anti-inflammatory effects on neutrophil recruitment. - **Colchicine** inhibits neutrophil *migration* (microtubule disruption), not recruitment (adhesion/chemokine-driven extravasation). - **Montelukast** blocks cysteinyl leukotriene receptors—primarily eosinophil-driven inflammation, not neutrophil recruitment. - In acute gout, **neutrophil infiltration** is the hallmark inflammatory event; febuxostat reduces flare frequency by suppressing this recruitment. ## Mnemonics **FXOB (Febuxostat's Unique Properties)** **F**ebuxostat = **X**anthine oxidase inhibitor + **O**utstanding anti-inflammatory (adhesion molecules) + **B**etter than allopurinol for neutrophil suppression. Use this to recall that febuxostat is the XO inhibitor with superior neutrophil-blocking properties. **Recruitment vs. Migration** **Recruitment** = adhesion molecules + chemokines (febuxostat blocks). **Migration** = microtubule dynamics (colchicine blocks). Recruitment happens *first* (rolling, adhesion, extravasation); migration happens *after* (cell movement in tissue). ## NBE Trap NBE pairs anti-inflammatory drugs (montelukast, colchicine, cromolyn) with neutrophil inhibition to test whether students understand the *mechanism* of neutrophil suppression. The trap is that all four options have anti-inflammatory effects, but only febuxostat specifically blocks the *recruitment* phase via adhesion molecule suppression. ## Clinical Pearl In Indian gout patients (often presenting with acute flares triggered by high-purine diet), febuxostat's dual benefit—uric acid lowering *plus* neutrophil recruitment inhibition—makes it superior to allopurinol for reducing flare frequency and severity, particularly in the first 6 months of urate-lowering therapy when flares are most common. _Reference: KD Tripathi Ch. 12 (Uricosuric and Uricolytics); Harrison Ch. 333 (Gout and Related Disorders)_